Literature DB >> 15479272

Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma.

A-M Hytönen1, O Löwhagen, M Arvidsson, B Balder, A L Björk, S Lindgren, M Hahn-Zoric, L A Hanson, L Padyukov.   

Abstract

BACKGROUND: Development of asthma is likely to depend on a complex interaction between environmental and genetic factors. Several groups have suggested the gene of the IL-4 receptor alpha chain (IL4R) as a candidate gene for the development of asthma, although association with single polymorphisms has shown contradicting results.
OBJECTIVE: We chose to analyse IL4R gene haplotypes and assess their possible relevance in susceptibility to asthma and to certain clinical phenotypes.
METHODS: IL4R gene haplotypes were analysed, based on the three markers C-3223T, Q551R and I50V, using the expectation-maximization algorithm, in 170 atopic asthma patients and 350 controls, all adult Swedish Caucasians.
RESULTS: Our data showed significantly higher levels of soluble IL-4R (sIL-4R) in asthma patients compared with controls (P<0.0001). Furthermore, we showed a significant association between the IL4R haplotype containing the alleles T-3223, V50 and R551 (TVR) of the IL4R gene, and susceptibility to atopic asthma, with a frequency of 6.5% in the patients compared with 1% in the controls (P<0.0005). A subgroup of patients with heterozygous or homozygous state for the T-3223, V50 and R551 alleles, also had lower levels of sIL-4R in their circulation compared with patients with homozygous state in the C-3223, I50 and Q551 alleles (P<0.05) and showed less severe asthma according to lung function test (P<0.05). Analysis of single markers showed the T-3223 IL4R allele to associate with lower serum levels of sIL-4 receptor (P<0.0001) and patients carrying the T allele also had more symptoms of active asthma (wheezing, P<0.01; coughing, P<0.05 and breathing difficulties, P<0.01).
CONCLUSION: Our data suggest that asthmatic patients with low levels of sIL-4 receptor may represent a genetically distinct subgroup of atopic asthma. TVR haplotype analyses confirm the importance of IL4R as a candidate gene for susceptibility to asthma. This finding may have implications for the understanding of the pathogenesis of asthma and possibly for the development of more specific therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479272     DOI: 10.1111/j.1365-2222.2004.02069.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  14 in total

1.  TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects.

Authors:  Christopher S Carlson; Patrick J Heagerty; Alex S Nord; David K Pritchard; Jane Ranchalis; Joshua M Boguch; Hangjun Duan; Thomas S Hatsukami; Stephen M Schwartz; Mark J Rieder; Deborah A Nickerson; Gail P Jarvik
Journal:  Hum Genet       Date:  2006-11-18       Impact factor: 4.132

2.  Ethnicity-specific gene-gene interaction between IL-13 and IL-4Ralpha among African Americans with asthma.

Authors:  Natalie C Battle; Shweta Choudhry; Hui-Ju Tsai; Celeste Eng; Gunjan Kumar; Kenneth B Beckman; Mariam Naqvi; Kelley Meade; H George Watson; Michael Lenoir; Esteban González Burchard
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 3.  Asthma from a pharmacogenomic point of view.

Authors:  C Szalai; I Ungvári; L Pelyhe; G Tölgyesi; A Falus
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

4.  IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression.

Authors:  Sally E Wenzel; Silvana Balzar; Elizabeth Ampleford; Gregory A Hawkins; William W Busse; William J Calhoun; Mario Castro; K Fan Chung; Serpil Erzurum; Benjamin Gaston; Elliot Israel; W Gerald Teague; Douglas Curran-Everett; Deborah A Meyers; Eugene R Bleecker
Journal:  Am J Respir Crit Care Med       Date:  2006-12-14       Impact factor: 21.405

5.  In vivo regulation of the allergic response by the IL-4 receptor alpha chain immunoreceptor tyrosine-based inhibitory motif.

Authors:  Raffi Tachdjian; Shadi Al Khatib; Andreas Schwinglshackl; Hong Sook Kim; Andrew Chen; Julie Blasioli; Clinton Mathias; Hye Young Kim; Dale T Umetsu; Hans C Oettgen; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

6.  Multilocus analysis of atopy in Korean children using multifactor-dimensionality reduction.

Authors:  Heung-Woo Park; Eun-Soon Shin; Jong-Eun Lee; Hyouk-Soo Kwon; Eunyoung Chun; Sun-Sin Kim; Yoon-Seok Chang; Yoon-Keun Kim; Kyung-Up Min; You-Young Kim; Sang-Heon Cho
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

7.  Lack of association of type 1 diabetes with the IL4R gene.

Authors:  H Q Qu; M C Tessier; R Fréchette; F Bacot; C Polychronakos
Journal:  Diabetologia       Date:  2006-03-15       Impact factor: 10.122

8.  A whole-genome scan for recurrent airway obstruction in Warmblood sport horses indicates two positional candidate regions.

Authors:  June E Swinburne; Helen Bogle; Jolanta Klukowska-Rötzler; Michaela Drögemüller; Tosso Leeb; Elizabeth Temperton; Gaudenz Dolf; Vincent Gerber
Journal:  Mamm Genome       Date:  2009-08       Impact factor: 2.957

9.  Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma.

Authors:  Raffi Tachdjian; Clinton Mathias; Shadi Al Khatib; Paul J Bryce; Hong S Kim; Frank Blaeser; Brian D O'Connor; Danuta Rzymkiewicz; Andrew Chen; Michael J Holtzman; Gurjit K Hershey; Holger Garn; Hani Harb; Harald Renz; Hans C Oettgen; Talal A Chatila
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

10.  Detection of R576 interleukin-4 receptor an allele gene, serum interleukin-4, and eosinophilic cationic protein in atopic dermatitis patients.

Authors:  M Y Abdel-Mawla; Y Mostafa; Y Abuel-Majd; Rasha Attwa
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.